Antibodies hold promise for breakthrough treatment of COVID-19, the disease caused by the coronavirus SARS-CoV-2.

Computer simulations of the evolution of broadly neutralizing antibodies against HIV suggest that non-traditional pathways involving framework mutations which lead initially to increased antibody flexibility do occur, but can be avoided by appropriate vaccine design.

This paper describes an effective pipeline for conversion of conventional monoclonal antibodies into recombinant form that results in an IgG subclass switch that greatly expands their utility for multiplex labeling.

Identification of viral and host determinants of broadly neutralizing antibodies targeting a new epitope on dengue virus that can be used to guide vaccine design.

A fully synthetic library of humanized single domain antibodies yields in vitro high affinity antibodies usable in cell biology and translational projects.

Single particle cryoEM structure of antibody complex with HIV-1 envelope trimer reveals new mode of asymmetric recognition of trimer apex.

The crystal structure of neutralizing antibody AR3X in complex with HCV E2 glycoprotein reveals unusual features of antibody recognition in which a conserved epitope is recognized by distinct antibody poses.

The association of atypical memory B-cells and autoimmune antibodies (anti-phosphatidylserine) with hemoglobin levels in malaria patients uncovers a novel mechanism for the human malaria-induced anemia previously identified in mice.

Combining pre-erythrocytic and transmission blocking antibodies enhances the overall control and potential elimination of malaria within both mosquito and vertebrate populations.

Modular tetravalent antibodies can be engineered to stimulate signaling through any combination of Frizzled and LRP receptors to drive organoid growth and mobilize endogenous stem cells in vivo.